We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

163 hedge funds and large institutions have $401M invested in Rigel Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 50 increasing their positions, 56 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more call options, than puts

Call options by funds: $1.35M | Put options by funds: $750K

13% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 16

10% more capital invested

Capital invested by funds: $365M → $401M (+$35.7M)

1% more funds holding

Funds holding: 162 → 163 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.19% less ownership

Funds ownership: 8.07% → 7.88% (-0.19%)

11% less repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 56

Holders
163
Holders Change
+1
Holders Change %
+0.62%
% of All Funds
2.57%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
18
Increased
50
Reduced
56
Closed
16
Calls
$1.35M
Puts
$750K
Net Calls
+$597K
Net Calls Change
+$710K

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$6.91M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$4.89M
3
IC
Ikarian Capital
Texas
+$4.6M
4
WP
Woodline Partners
California
+$2.23M
5
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$2.04M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$5.54M
2
TA
Tamarack Advisers
California
-$3.38M
3
Goldman Sachs
Goldman Sachs
New York
-$3.13M
4
HP
HealthInvest Partners
Sweden
-$2.89M
5
State Street
State Street
Massachusetts
-$2.82M
Name Holding Trade Value Shares
Change 		Change in
Stake
Janus Henderson Group
101
Janus Henderson Group
United Kingdom
$102K – – –
BC
102
Burney Company
Virginia
$96K – – –
AQR Capital Management
103
AQR Capital Management
Connecticut
$93K -$40.3K -1,488 -32%
AB
104
Amalgamated Bank
New York
$83K -$6.36K -235 -8%
AF
105
Amalgamated Financial
New York
$83K +$75.3K +2,782 New
TRCT
106
Tower Research Capital (TRC)
New York
$80K -$94K -3,472 -57%
Zurich Cantonal Bank
107
Zurich Cantonal Bank
Switzerland
$80K -$42.7K -1,577 -37%
PWPS
108
Pinnacle Wealth Planning Services
Ohio
$79K +$7.77K +287 +12%
PWA
109
Providence Wealth Advisors
Illinois
$75K – – –
DAS
110
Dynamic Advisor Solutions
Arizona
$64K – – –
Mackenzie Financial
111
Mackenzie Financial
Ontario, Canada
$60K – – –
MIM
112
Marco Investment Management
Georgia
$60K – – –
KFA
113
Kelleher Financial Advisors
New York
$59K -$217K -8,000 -80%
BJL
114
Brighton Jones LLC
Washington
$58K +$271 +10 +0.5%
PAMS
115
Pictet Asset Management (Switzerland)
Switzerland
$57K – – –
CSS
116
Cubist Systematic Strategies
Connecticut
$55K -$7.31K -270 -13%
Squarepoint
117
Squarepoint
New York
$53K -$366K -13,518 -88%
EFM
118
E Fund Management
China
$52K +$3.79K +140 +9%
FPCP
119
Fort Point Capital Partners
California
$51K – – –
SM
120
Sciencast Management
New Jersey
$49K +$42.5K +1,568 New
Royal Bank of Canada
121
Royal Bank of Canada
Ontario, Canada
$46K -$72.9K -2,692 -63%
Balyasny Asset Management
122
Balyasny Asset Management
Illinois
$46K +$41.9K +1,549 New
Victory Capital Management
123
Victory Capital Management
Texas
$45K -$785 -29 -2%
AIP
124
Ameritas Investment Partners
Nebraska
$44K – – –
BNP Paribas Financial Markets
125
BNP Paribas Financial Markets
France
$41.7K -$55.8K -2,060 -60%
3 4
5
6 7

RIGL Hedge Fund Activity: Q1 2022 in Review

163 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q1 2022, worth a combined $401M — up 9.8% from $365M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new RIGL positions and 16 closed out — a net gain of 2 holders — while 50 added to existing stakes and 56 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $6.91M. The largest seller was Millennium Management, cutting an estimated $5.54M.

  • 163 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q1 2022, up from 162 in Q4 2021.
  • Funds reported $401M of Rigel Pharmaceuticals stock for Q1 2022, up 9.8% quarter-over-quarter.
  • 18 funds opened new Rigel Pharmaceuticals positions in Q1 2022 and 16 closed out, a net change of +2 holders.
  • The largest Rigel Pharmaceuticals buyer in Q1 2022 was Citadel Advisors, an estimated $6.91M added.
  • The largest Rigel Pharmaceuticals seller in Q1 2022 was Millennium Management, an estimated $5.54M sold.

Based on aggregated 13F filings for Q1 2022.